Tag : METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE

HCC risk in MASLD extends beyond established cirrhosis, highlighting the need for more granular fibrosis-based risk stratification. A sequential approach, using the FIB-4 index for initial screening followed by liver stiffness measurement, may help identify patients at higher HCC risk who warrant further evaluation for surveillance and specialist referral.

MASLD drives persistent HCC risk despite HCV cure: Insights from a Japanese multicenter cohort study

